NCT01699152已完成1 期
Phase 1 Dose-Escalation and Pharmacokinetic Study of TG02 Citrate in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 16
- 试验地点
- 5
- 主要终点
- Maximum Tolerated Dose
研究概览
简要总结
This is a multi-center, open-label, dose escalation study.
详细描述
The primary objective is to determine the highest dose of TG02 citrate that can be safely given to patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have histologically confirmed Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma.
- •Patients must meet one or more of the following indications for treatment:
- •Progressive disease or marked splenomegaly and/or lymphadenopathy.
- •Anemia (hemoglobin <11 mg/dL) or thrombocytopenia (platelets<100,000/μL).
- •Unexplained weight loss exceeding 10% of body weight over the previous 6 months.
- •CTCAE Grade 2 or 3 fatigue.
- •Fevers >100.5º F or night sweats for more than 2 weeks without evidence of infection.
- •Progressive lymphocytosis, with an increase exceeding 50% over a 2 month period or a doubling time of less than 6 months.
- •Need for cytoreduction prior to allogeneic stem cell transplant.
- •Patients must have relapsed or refractory disease after ≥1 prior line of treatment.
- •The interval from prior treatment to time of study drug administration should be at least 5 half-lives for cytotoxic and noncytotoxic agents.
- •Low-dose corticosteroids (prednisone <20 mg/ day or equivalent dose) are permitted throughout study.
- •Clinically significant toxicities from prior chemotherapy must be resolved to Grade ≤
- •Age >18 years.
- •ECOG performance status ≤
- •Life expectancy ≥ 12 weeks.
- •Patients must have normal organ and marrow function as defined below:
- •absolute neutrophil count >1,000/μL in absence of bone marrow involvement
- •platelets ≥30,000/μL in absence of bone marrow involvement
- •If patient has extensive bone marrow involvement, minimum ANC and platelet levels are not required.
- •total bilirubin ≤1.5 X institutional ULN unless due to Gilbert's syndrome, controlled autoimmune hemolytic anemia or immune thrombocytopenia
- •AST(SGOT)/ALT(SGPT) <2.5 X institutional ULN unless due to disease
- •creatinine <2.0 mg/dL OR creatinine clearance >50 mL/min/1.73 m2
- •Negative serum or urine pregnancy test at the time of first dose for WOCBP.
- •Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and to return for required assessments.
- •Ability to take oral medication.
排除标准
- •Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (CTCAE Grade > 1) due to agents administered more than 3 weeks earlier.
- •Patients who have received prior treatment with a CDK inhibitor within 12 months of study enrollment.
- •High-dose corticosteroids (prednisone ≥20mg/day or equivalent dose) must be discontinued ≥ 7 days of initiating therapy.
- •Patients with known central nervous system involvement.
- •History of allergic reactions attributed to compounds of similar chemical or biologic composition as TG02 citrate.
- •Patients with G6PD deficiency.
- •Concurrent severe or uncontrolled medical disease (including but not limited to history of ventricular arrhythmia or symptomatic conduction abnormality within 12 months, ongoing or active systemic infection, diabetes, hypertension, coronary artery disease, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations) that, in the opinion of the Investigator, would compromise the safety of the patient or compromise the ability of the patient to complete the study.
- •Pregnant and/or breast-feeding women.
- •Prior or second malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical or breast cancer, or other cancer for which the subject has received curative therapy at least 3 years prior to study entry.
- •Known HIV or AIDs.
- •QTc interval prolongation >450ms for males and >470 ms for females.
研究组 & 干预措施
TG02 citrate
Experimental
TG02 citrate capsules given orally.
干预措施: TG02 citrate (Drug)
结局指标
主要结局
Maximum Tolerated Dose
时间窗: 28 days
To assess the number of patients with dose-limiting toxicities (DLT) and the dose of TG02 citrate that can be safely given to patients with CLL or SLL.
次要结局
- Adverse Events(28 days)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
1 期
Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological MalignanciesALLBlast CrisisMDSMultiple MyelomaAMLNCT01204164Tragara Pharmaceuticals, Inc.120
Unknown
1 期
Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and LymphomaLymphomaMultiple MyelomaNCT04818372Keymed Biosciences Co.Ltd87
撤回
1 期
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.Non-small Cell Lung Cancer (NSCLC)EndometrialSolid TumorsOvarian CancerLiposarcomaBreast CancerNCT05905341Pfizer
已完成
1 期
Phase 1 Study of TG01 and Erlotinib in Non-small Cell Lung Cancer (NCSLC) PatientsNon-small Cell Lung CancerNCT00569114Tragara Pharmaceuticals, Inc.45
已完成
1 期
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901Pancreatic CancerNCT04805307Keymed Biosciences Co.Ltd176